Results 61 to 70 of about 19,722 (182)

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface*

Journal of Biological Chemistry, 2015
Bcr-Abl is a constitutively active kinase that causes chronic myelogenous leukemia. We have shown that a tandem fusion of two designed binding proteins, termed monobodies, directed to the interaction interface between the Src homology 2 (SH2) and kinase ...
John B Wojcik, A. Lamontanara, G. Grabe, A. Koide, Louesa R. Akin, Barbara Gerig, O. Hantschel, S. Koide   +7 more
semanticscholar   +1 more source

Eosinofilia reacional, leucemia eosinofílica crônica e síndrome hipereosinofílica idiopática Reactive eosinophilia, chronic eosinophilic leukemia and idiopathic hypereosinophilic syndrome

Revista Brasileira de Hematologia e Hemoterapia, 2010
A eosinofilia é freqüente na prática clínica, principalmente quando os valores estão entre 500 e 1000 eosinófilos/uL e indica a presença de doença parasitária, alérgica ou reação a medicamentos.
Maria de Lourdes Lopes Ferrari Chauffaille
doaj   +1 more source

Detection of a rare BCR–ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS) [PDF]

Proceedings of the National Academy of Sciences, 2012
Hypothesis directed proteomics offers higher throughput over global analyses. We show that immunoprecipitation (IP)–tandem mass spectrometry (LC-MS/MS) in H929 multiple myeloma (MM) cancer cells led to the discovery of a rare and unexpected BCR–ABL fusion, informing a therapeutic intervention using imatinib (Gleevec). BCR–ABL is the driving mutation in
Susanne B. Breitkopf, John M. Asara, John M. Asara, Min Yuan, German Pihan   +4 more
openaire   +2 more sources

New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia

Oncoscience, 2015
In Chronic Myeloid Leukemia 80% of patients present alternative splice variants involving BCR exons 1, 13 or 14 and ABL exon 4, with a consequent impairment in the reading frame of the ABL gene.
C. Panuzzo, G. Volpe, E. C. Rocchietti, C. Casnici, K. Crotta, S. Crivellaro, Giovanna Carrá, Roberta Lorenzatti, Barbara Peracino, Davide Torti, A. Morotti, M. P. Camacho-Leal, P. Defilippi, O. Marelli, G. Saglio   +14 more
semanticscholar   +1 more source

BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.

Blood, 1996
Chronic myelogenous leukemia (CML) is characterized by the t(9;22) translocation that results in chimeric genes encoding bcr/abl fusion proteins. Junction-spanning sequences represent unique tumor-specific moieties that might be exploited therapeutically.
Graham Pawelec, H. Max, T. Halder, O. Bruserud, A. Merl, P. D. Silva, Hubert Kalbacher   +6 more
semanticscholar   +1 more source

Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment

MedComm, Volume 6, Issue 6, June 2025.
Currently, a variety of methods such as flow cytometry, polymerase chain reaction, next‐generation sequencing, and other emerging methods are used for the detection of minimal residual disease, each of which has its own unique strengths and limitations and, more importantly, promising clinical applications.
Meiling Song, Wenjing Pan, Xinjie Yu, Jie Ren, Congli Tang, Zhu Chen, Zhe Wang, Yan Deng, Nongyue He, Hongna Liu, Song Li   +10 more
wiley   +1 more source

Phase Separation: A New Dimension to Understanding Tumor Biology and Therapy

MedComm – Oncology, Volume 4, Issue 2, June 2025.
Liquid–liquid phase separation (LLPS) facilitates the assembly of biomolecular condensates by leveraging weak multivalent interactions. The low‐complexity domains, foldable domains of proteins, and nucleic acids provide multivalent interaction sites among different molecules and contribute to the formation of condensates.
Xingwen Wang, Minqiao Lu, Yi Zhang, Jiangwen Ma, Ying Hu   +4 more
wiley   +1 more source

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

Leukemia, 2013
Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies.
M. Scherr, A. Elder, K. Battmer, D. Barzan, S. Bomken, M. Ricke-Hoch, A. Schro¨der, L. Venturini, H. Blair, J. Vormoor, O. Ottmann, A. Ganser, A. Pich, D. Hilfiker-Kleiner, O. Heidenreich, M. Eder   +15 more
semanticscholar   +1 more source

Novel clinical trial designs emerging from the molecular reclassification of cancer

CA: A Cancer Journal for Clinicians, Volume 75, Issue 3, Page 243-267, May/June 2025.
Abstract Next‐generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease,
Mina Nikanjam, Shumei Kato, Teresa Allen, Jason K. Sicklick, Razelle Kurzrock   +4 more
wiley   +1 more source

The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.

Blood, 2001
This report describes 2 patients with a clinical and hematologic diagnosis of chronic myeloid leukemia (CML) in chronic phase who had an acquired t(8;22)(p11;q11). Analysis by fluorescence in situ hybridization (FISH) and reverse transcription-polymerase
Asuman Demiroglu, E. Steer, C. Heath, K. Taylor, M. Bentley, S. L. Allen, P. Koduru, J. Brody, G. Hawson, R. Rodwell, Marylou Doody, F. Carnicero, A. Reiter, J. Goldman, J. Melo, Nicholas C. P. Cross   +15 more
semanticscholar   +1 more source